Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 6/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 4/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 3/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340548 | 0.95 | PIM1 (0.42) | CDC7SCN5ASCN9AJAK2JAK3 | |
| SCHEMBL3343878 | 0.86 | CDC7 (0.44) | CDC7SCN5ASCN9AJAK2JAK3 | |
| SCHEMBL3339626 | 0.84 | XDH (0.44) | CDC7SCN5ASCN9AJAK2JAK3 | |
| SCHEMBL3340105 | 0.84 | CDC7 (0.52) | CDC7JAK2JAK3JAK1TYK2 | |
| SCHEMBL3338667 | 0.81 | CDC7 (0.47) | CDC7SCN5ASCN9AJAK2JAK3 | |
| SCHEMBL3340296 | 0.80 | CDC7 (0.49) | CDC7JAK2PIM1MAPK13DAPK3 | |
| SCHEMBL3338793 | 0.78 | PIM1 (0.50) | CDC7JAK2JAK3JAK1TYK2 | |
| SCHEMBL3345741 | 0.78 | CDC7 (0.45) | CDC7PDE5APDE4APDE4BPDE4C | |
| SCHEMBL3341820 | 0.77 | CDC7 (0.43) | CDC7JAK2JAK3TYK2MAPK13 | |
| SCHEMBL383302 | 0.77 | CDC7 (0.62) | CDC7JAK2JAK3JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074114-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2013-03-06 | — | — | EP | claimed |
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. (US) | 2010-06-10 | — | — | US | claimed |
| EP-2074114-A1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| WO-2008143759-A1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2008-11-27 | — | — | WO | claimed |
| EP-2074114-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2074114-A1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008143759-A1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | CSNK2A1, CSNK2A2, CSNK1A1 | CDC7 532/4885SCN5A 2365/4885SCN9A 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.